Eupraxia Pharmaceuticals Ratios and Metrics

Market cap in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2017
Period Ending	Apr '26 Apr 28, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2017
Market Capitalization	601	523	161	147	79	35	Upgrade
Market Cap Growth	306.83%	225.34%	9.66%	85.89%	125.87%	-	Upgrade
Enterprise Value	529	441	147	127	58	10	Upgrade
Last Close Price	9.77	10.32	4.51	5.37	3.65	2.45	Upgrade
PB Ratio	5.45	4.74	3.51	124.32	8.08	1.83	Upgrade
P/TBV Ratio	8.38	7.29	65.70	50.06	7.48	1.75	Upgrade
Debt / Equity Ratio	0.00	0.00	0.00	11.71	1.25	0.52	Upgrade
Net Debt / Equity Ratio	-1.00	-1.00	-1.04	-9.96	-1.29	-1.04	Upgrade
Net Debt / EBITDA Ratio	2.10	2.10	1.23	0.32	0.53	1.12	Upgrade
Net Debt / FCF Ratio	2.76	2.76	1.10	0.43	0.63	1.31	Upgrade
Quick Ratio	14.44	14.44	10.74	1.01	6.00	13.38	Upgrade
Current Ratio	15.12	15.12	11.10	1.02	6.08	13.49	Upgrade
Return on Equity (ROE)	-68.76%	-68.76%	-157.31%	-715.19%	-178.04%	-	Upgrade
Return on Assets (ROA)	-39.67%	-39.67%	-61.14%	-88.37%	-52.20%	-68.51%	Upgrade
Return on Capital Employed (ROCE)	-47.70%	-47.70%	-84.80%	-3120.70%	-109.70%	-61.90%	Upgrade
Earnings Yield	-9.38%	-10.12%	-22.84%	-25.44%	-31.75%	-68.66%	Upgrade
FCF Yield	-6.65%	-7.64%	-26.96%	-18.77%	-25.12%	-43.73%	Upgrade
Buyback Yield / Dilution	-17.76%	-17.76%	-40.52%	-25.21%	-55.45%	-102.75%	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.